
Memo Therapeutics AG raises CHF25m
The CHF25m Series C round of Schlieren-based Memo Therapeutics AG was led by Pureos Bioventures. Existing investors Swisscanto, Vesalius Biocapital,...

Abingworth raises $356m for new CCD fund
London-headquartered institutional investor Abingworth has closed its new Clinical Co-Development Co-Investment Fund at $356m, exceeding its target...

Cellectis and AstraZeneca in US$2.2bn deal
Under the co-development agreement, that includes a US$80m equity investment and an option for a further equity investment of US$140m by AstraZeneca...

Study: New breeding methods hardly contribute to climate protection
Up and down the country, national governments and the EU Commission (EC) are campaigning to facilitate the commercialisation of cis-gentic and...

Crucible Therapeutics spins out with £5m
Crucible Therapeutics Ltd., the newly launched spinout company from the University of Sheffield, secured the investment of £5m from Northern...

German company aims for the first EU approval for cell-cultured meat
The Cultivated B (Heidelberg, Germany) is the first company in the world to pre-register a partially cell-based meat product with the European Food...